Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.59 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525977 | 0.90 | HSP90AB1 (0.56) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3415389 | 0.90 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL18096418 | 0.89 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15525975 | 0.89 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15522262 | 0.89 | HSP90AA1 (0.60) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15521954 | 0.88 | HSP90AA1 (0.56) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL17099717 | 0.86 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL28343535 | 0.86 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL20879065 | 0.86 | HSP90AA1 (0.57) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL501442 | 0.86 | HSP90AA1 (0.62) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117944-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170014519-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8993608-B2 | Method for inhibiting topoisomerase II | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AB1 6/4885HSP90AA1 8/4885HSP90B1 5/4885 |
| US-20170014519-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AB1 6/4885HSP90AA1 8/4885HSP90B1 5/4885 |
| US-10117944-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.